Structure Therapeutics (GPCR) Interest Coverage Ratio (2022 - 2026)
Structure Therapeutics (GPCR) posted quarterly Interest Coverage Ratio of 111.72 for Q1 2026, down 19.04% year-over-year from 138.0 in Q1 2025, and down 472.58% quarter-over-quarter from 29.99 in Q4 2025.
Structure Therapeutics (GPCR) Interest Coverage Ratio (2022 - 2026) Analysis & Trends
Structure Therapeutics' Interest Coverage Ratio history runs 5 years deep, the most recent figure standing at 111.72 for Q1 2026.
- In Q1 2026, Interest Coverage Ratio fell 19.04% year-over-year to 111.72; the TTM figure through Mar 2026 stood at 80.63 (up 33.74% YoY), while the FY2025 annual figure was 0.7, up 70.04% from the prior year.
- Interest Coverage Ratio for Q1 2026 stood at 111.72, down from 29.99 in the prior quarter.
- The five-year high for Interest Coverage Ratio was 29.99 in Q4 2025, with the low at 139.6 in Q2 2022.
- The 5-year median for Interest Coverage Ratio is 55.3 (2025), against an average of 56.63.
- Peak annual rise in Interest Coverage Ratio reached 125.49% in 2025, while the deepest fall reached 32020.63% in 2025.
- Structure Therapeutics' Interest Coverage Ratio stood at 129.56 in 2022, then jumped by 40.19% to 77.48 in 2023, then sank by 51.84% to 117.65 in 2024, then jumped by 125.49% to 29.99 in 2025, then slumped by 472.58% to 111.72 in 2026.
- Business Quant data shows GPCR's Interest Coverage Ratio at 111.72 in Q1 2026, 29.99 in Q4 2025, and 9.31 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Structure Therapeutics | 11.65 Bn | 11.65 Bn | - | -17.32 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -17.32 |
| Mar 31, 2026 | -111.72 |
| Dec 31, 2025 | 29.99 |
| Sep 30, 2025 | -9.31 |
| Jun 30, 2025 | -55.30 |
| Mar 31, 2025 | -93.85 |
| Dec 31, 2024 | -117.65 |
| Sep 30, 2024 | -0.43 |
| Jun 30, 2024 | -0.37 |
| Mar 31, 2024 | -0.29 |
| Dec 31, 2023 | -77.49 |
| Sep 30, 2023 | -0.16 |
| Jun 30, 2023 | -0.20 |
| Mar 31, 2023 | -0.34 |
| Dec 31, 2022 | -129.56 |
| Sep 30, 2022 | -126.93 |
| Jun 30, 2022 | -139.60 |
| Mar 31, 2022 | -129.52 |